Top

Published in:

04-02-2024 | Aplastic Anemia | Progress in Hematology

Aplastic anemia: history and recent developments in diagnosis and treatment

Author: Yasushi Onishi

Published in: International Journal of Hematology | Issue 3/2024

Abstract

Acquired aplastic anemia is an immune-mediated disease that targets hematopoietic stem cells, which is diagnosed by findings of peripheral blood pancytopenia and hypocellular bone marrow. Although the diagnostic definition is simple, differential diagnosis from other overlapping hematopoietic disorders such as hypoplastic myelodysplastic syndrome and inherited bone marrow failure syndrome is not easy. Immune suppressive therapy and allogeneic hematopoietic stem cell transplantation are important treatment approaches for aplastic anemia, and both have advanced in recent years. This issue of Progress in Hematology covers four topics related to aplastic anemia: (1) laboratory markers to identify immune pathophysiology and their role on differential diagnosis and prognosis, (2) the path to combination therapy with horse anti-thymocyte globulin, cyclosporine A, and eltrombopag, (3) more than 60 years of history and recent trends in allogeneic HSCT, and (4) genetic testing for differential diagnosis from IBMFS and novel approaches to transplantation for children including fludarabine/melphalan-based conditioning.

Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509–19. https://doi.org/10.1182/blood-2006-03-010777.CrossRefPubMedPubMedCentral

Montane E, Ibanez L, Vidal X, Ballarin E, Puig R, Garcia N, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93(4):518–23. https://doi.org/10.3324/haematol.12020.CrossRefPubMed

Issaragrisil S, Chansung K, Kaufman DW, Sirijirachai J, Thamprasit T, Young NS. Aplastic anemia in rural Thailand: its association with grain farming and agricultural pesticide exposure. aplastic anemia study group. Am J Public Health. 1997;87(9):1551–4. https://doi.org/10.2105/ajph.87.9.1551.CrossRefPubMedPubMedCentral

Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55-CD59-blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107(4):1308–14. https://doi.org/10.1182/blood-2005-06-2485.CrossRefPubMed

Katagiri T, Sato-Otsubo A, Kashiwase K, Morishima S, Sato Y, Mori Y, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood. 2011;118(25):6601–9. https://doi.org/10.1182/blood-2011-07-365189.CrossRefPubMed

Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med. 1983;308(3):113–8. https://doi.org/10.1056/NEJM198301203080301.CrossRefPubMed

Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The german aplastic anemia study group. New Engl J Med. 1991;324(19):1297–304. https://doi.org/10.1056/NEJM199105093241901.CrossRefPubMed

Patel BA, Groarke EM, Lotter J, Shalhoub R, Gutierrez-Rodrigues F, Rios O, et al. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study. Blood. 2022;139(1):34–43. https://doi.org/10.1182/blood.2021012130.CrossRefPubMedPubMedCentral

Peffault de Latour R, Kulasekararaj A, Iacobelli S, Terwel SR, Cook R, Griffin M, et al. Eltrombopag added to immunosuppression in severe aplastic anemia. New Engl J Med. 2022;386(1):11–23. https://doi.org/10.1056/NEJMoa2109965.CrossRefPubMed

10.

Thomas ED, Storb R, Fefer A, Slichter SJ, Bryant JI, Buckner CD, et al. Aplastic anaemia treated by marrow transplantation. Lancet. 1972;1(7745):284–9. https://doi.org/10.1016/s0140-6736(72)90292-9.CrossRefPubMed

11.

Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314(12):729–35. https://doi.org/10.1056/NEJM198603203141201.CrossRefPubMed

12.

Storb R, Etzioni R, Anasetti C, Appelbaum FR, Buckner CD, Bensinger W, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84(3):941–9.CrossRefPubMed

13.

DeZern AE, Zahurak ML, Symons HJ, Cooke KR, Rosner GL, Gladstone DE, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4(8):1770–9. https://doi.org/10.1182/bloodadvances.2020001729.CrossRefPubMedPubMedCentral

14.

DeZern A, Zahurak ML, Symons HJ, Cooke KR, Huff CA, Jain T, et al. Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. Blood. 2023. https://doi.org/10.1182/blood.2023020435.CrossRefPubMed

15.

Yamamoto H, Kato D, Uchida N, Ishiwata K, Araoka H, Takagi S, et al. Successful sustained engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with severe aplastic anemia. Blood. 2011;117(11):3240–2. https://doi.org/10.1182/blood-2010-08-295832.CrossRefPubMed

16.

Ochi T, Onishi Y, Nasu K, Onodera K, Kobayashi M, Ichikawa S, et al. Umbilical cord blood transplantation using reduced-intensity conditioning without antithymocyte globulin in adult patients with severe aplastic anemia. Biol Blood Marrow Transplant. 2019;25(2):e55–9. https://doi.org/10.1016/j.bbmt.2018.09.039.CrossRefPubMed

17.

Hiramoto N, Yamazaki H, Nakamura Y, Uchida N, Murata M, Kondo T, et al. Total body irradiation-containing conditioning regimens without antithymocyte globulin in adults with aplastic anemia undergoing umbilical cord blood transplantation. Ann Hematol. 2022;101(1):165–75. https://doi.org/10.1007/s00277-021-04664-z.CrossRefPubMed

18.

Onishi Y, Mori T, Kako S, Koh H, Uchida N, Kondo T, et al. Outcome of second transplantation using umbilical cord blood for graft failure after allogeneic hematopoietic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2017;23(12):2137–42. https://doi.org/10.1016/j.bbmt.2017.08.020.CrossRefPubMed

19.

Onishi Y, Mori T, Yamazaki H, Hiramoto N, Zaimoku Y, Kanaya M, et al. Comparison of haploidentical stem cell transplantation with post-transplantation cyclophosphamide versus umbilical cord blood transplantation in adult patients with aplastic anemia. Transplant Cell Ther. 2023;29(12):766 e1 e8. https://doi.org/10.1016/j.jtct.2023.09.009.CrossRef

20.

Yoshida N, Takahashi Y, Yabe H, Kobayashi R, Watanabe K, Kudo K, et al. Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide. Bone Marrow Transplant. 2020;55(7):1272–81. https://doi.org/10.1038/s41409-020-0948-8.CrossRefPubMed

Title: Aplastic anemia: history and recent developments in diagnosis and treatment
Author: Yasushi Onishi
Publication date: 04-02-2024
Publisher: Springer Nature Singapore
Keywords: Aplastic Anemia
Myelodysplastic Syndrome
Hematology
Published in: International Journal of Hematology / Issue 3/2024
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-024-03715-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2024

Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia

Allogeneic bone marrow transplantation for aplastic anemia

Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors

HLA-haploidentical T-cell receptor αβT/B-cell-depleted stem cell transplantation for Fanconi anemia

Progress in medical therapy in aplastic anemia: why it took so long?

Histiocytic sarcoma following CAR T-cell therapy: a case report

Keynote webinar | Spotlight on antibody–drug conjugates in cancer